Kenneth Janzon
Chief Tech/Sci/R&D Officer bij Nordvacc Läkemedel AB
Vermogen: 396 723 $ op 31-03-2024
Profiel
Kenneth Janzon is the founder of Intervacc AB, which was founded in 2001.
He held the title of Independent Director at Intervacc AB.
Currently, Mr. Janzon is the Chief Technical Officer at Nordvacc Läkemedel AB.
Bekende belangen in openbare bedrijven
Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
---|---|---|---|---|
INTERVACC AB
1.51% | 30-06-2023 | 1 146 500 ( 1.51% ) | 396 723 $ | 31-03-2024 |
Actieve functies van Kenneth Janzon
Bedrijven | Functie | Begin |
---|---|---|
Nordvacc Läkemedel AB
Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The private company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Chief Tech/Sci/R&D Officer | - |
Eerdere bekende functies van Kenneth Janzon
Bedrijven | Functie | Einde |
---|---|---|
INTERVACC AB | Founder | 14-06-2018 |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
INTERVACC AB | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
Nordvacc Läkemedel AB
Nordvacc Läkemedel AB Medical DistributorsDistribution Services Part of Intervacc AB, Nordvacc Läkemedel AB is a veterinary pharmaceutical company based in Hägersten, SE. Nordvacc Läkemedel AB was acquired by Sorkaruga AB on March 25, 2014. The Swedish company specializes in the distribution and marketing of veterinary vaccines and medicines for the care and treatment of both companion and farm animals. The private company's flagship product, infucal® vet, is a solution for calving paralysis and is vital for the survival of cattle. The product contains calcium, magnesium, a source of phosphorus in the form of sodium hypophosphite, and glucose, which counteracts hypomagnesemia and is used to treat other conditions with hypocalcemia in animals. The CEO of the company is Rune Bergman. | Distribution Services |